Phase II study of mitoxantrone for liver metastases from breast cancer
β Scribed by S. M. O'Reilly; R. E. Coleman; R. D. Rubens
- Publisher
- Springer
- Year
- 1989
- Tongue
- English
- Weight
- 197 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0344-5704
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Forty-nine patients with histologically conlirmed primary liver cancer have been entered on phase II trials of mitoxantrone (NovantroneC"~; dihydroxyanthracenedione), at a dose of 14 mg/m 2 every 3 weeks. Among the patients evaluable for toxicity, leukopenia and thrombocytopenia were the most import
To determine the effect of aggressive regional therapy for liver metastasis from breast cancer, we retrospectively reviewed data on 74 patients identified with liver metastases. Forty had only liver metastases. In this group of 40 patients, 18 were treated with regional therapy only, i.e., surgical